Treatment with Metformin [48,69], GLP-1 receptor agonists [70], and DPP-4 inhibitors [71] have been shown to favorably alter GM composition in T2D, suggesting that antidiabetic treatment may restore the gut microbial diversity toward that seen in healthy individuals. Here, GLP1R is linked to type 2 diabetes mellitus.